Jabre Capital Partners’s Kite Pharma, Inc. KITE Stock Holding History

Jabre Capital Partners’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,000	Closed	-$207K	–	152
2017 Q2	$207K	Buy	+2,000	New	+$163K	0.02%	123

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jabre Capital Partners's KITE Position: Q3 2017 in Review

Jabre Capital Partners sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 2,000 shares — an estimated $207K sold.

Jabre Capital Partners first reported a position in KITE in Q2 2017 and held it in 1 quarter. The position peaked at $207K in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Jabre Capital Partners reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Jabre Capital Partners sold 2,000 Kite Pharma, Inc. shares in Q3 2017, an estimated $207K.
Jabre Capital Partners first reported a position in Kite Pharma, Inc. in Q2 2017 and held it in 1 quarter.
Jabre Capital Partners's Kite Pharma, Inc. position peaked at $207K in Q2 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Jabre Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.